To support their rapid growth and expanding portfolio of rare disease programs, Aeglea Biotherapeutics retained The Chase Group and successfully secured a new Global Program Lead for their Early Pipeline Programs. To unlock the potential of next-generation human enzymes, Aeglea requires exceptional individuals who bring tremendous skill and talent with their experience. With 25+ years of experience in executive search, The Chase Group was able to utilize their vast network of life science professionals to identify the successful candidate. Reporting to the Chief Medical Officer, this respected and versatile leader is responsible for shaping the program strategy and generating data from clinical development activities. The Chase Group is honored to partner with Aeglea and support their dedication and passion to improve the lives of patients with unmet medical needs.
Aeglea Biotherapeutics Secures Another Executive for their Clinical Development Leadership Team
To support their rapid growth and expanding portfolio of rare disease programs, Aeglea Biotherapeutics retained The Chase Group and successfully secured a new Global Program Lead for their Early Pipeline Programs. To unlock the potential of next-generation human enzymes, Aeglea requires exceptional individuals who bring tremendous skill and talent with their experience. With 25+ years of experience in executive search, The Chase Group was able to utilize their vast network of life science professionals to identify the successful candidate. Reporting to the Chief Medical Officer, this respected and versatile leader is responsible for shaping the program strategy and generating data from clinical development activities. The Chase Group is honored to partner with Aeglea and support their dedication and passion to improve the lives of patients with unmet medical needs.- Categories: Life Sciences
Ionis Director, Global HEOR, Rare Disease Immunology, Successfully Placed by The Chase Group
Director, Global HEOR Rare Disease Immunology reporting to Montserrat Vera-Llonch was filled for Ionis. This is a critical and significant role as the commercial function…
Successful Placement at Avidity
The Chase Group is pleased to announce the successful completion of the Vice President, Medical Affairs search for Avidity Biosciences. Nathan Weedin brings 15+ years…
The Chase Group Successfully Completes Search for Amyloidosis Medical Affairs Leader
Ionis Pharmaceuticals has a 35-year track record of perfecting and advancing RNA-targeted drug discovery and development. Projecting a vast number of new transformational products on…
The Chase Group Identifies Chief Medical Officer for Arcturus Therapeutics
In late 2022, Arcturus Therapeutics retained The Chase Group to build out additions to the leadership team. Tasked with identifying the new Chief Medical Officer,…
The Chase Group Secures VP, Head of Regulatory Affairs, for Checkmate Pharmaceuticals
The Chase Group is pleased to announce the successful recruitment of Elvis Osei Tutu, PharmD, as the Vice President, Head of Regulatory Affairs at Checkmate…
The Chase Group Secures Clinical Operations Leadership for Alexza Pharmaceuticals
The Chase Group, committed to executive recruitment in life sciences, is pleased to announce the completion of another search for Alexza Pharmaceuticals, successfully securing Mike…